


Accepted Manuscript

EIF2AK4 Mutations in Patients Diagnosed with Pulmonary Arterial Hypertension

D. Hunter Best, PhD, Kelli L. Sumner, BS, Benjamin P. Smith, MD, Kristy Damjanovich-Colmenares, BS, Ikue Nakayama, MD, Lynette M. Brown, MD, PhD, Youna Ha, BS, Eleri Paul, MLS (ASCP), Ashley Morris, MLS (ASCP), Mohamed A. Jama, MS, MB (ASCP), Mark W. Dodson, MD, PhD, Pinar Bayrak-Toydemir, MD, PhD, C. Gregory Elliott, MD, MACP, FCCP



PII: S0012-3692(16)62396-6

DOI: [10.1016/j.chest.2016.11.014](https://doi.org/10.1016/j.chest.2016.11.014)

Reference: CHEST 821

To appear in: *CHEST*

Received Date: 14 June 2016

Revised Date: 18 October 2016

Accepted Date: 4 November 2016

Please cite this article as: Best DH, Sumner KL, Smith BP, Damjanovich-Colmenares K, Nakayama I, Brown LM, Ha Y, Paul E, Morris A, Jama MA, Dodson MW, Bayrak-Toydemir P, Elliott CG, *EIF2AK4* Mutations in Patients Diagnosed with Pulmonary Arterial Hypertension, *CHEST* (2016), doi: 10.1016/j.chest.2016.11.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Word Count: Abstract 247; Body 2528

***EIF2AK4* Mutations in Patients Diagnosed with Pulmonary Arterial Hypertension**

Short running title: ***EIF2AK4* Mutations in PAH**

Authors: D. Hunter Best, PhD^{*1-3}, Kelli L. Sumner, BS^{*1}, Benjamin P. Smith, MD^{4,5}, Kristy Damjanovich-Colmenares, BS¹, Ikue Nakayama, MD⁴, Lynette M. Brown, MD, PhD^{4,5}, Youna Ha, BS¹, Eleri Paul, MLS (ASCP)¹, Ashley Morris, MLS (ASCP)¹, Mohamed A. Jama, MS, MB (ASCP)¹, Mark W. Dodson, MD, PhD^{4,5}, Pinar Bayrak-Toydemir, MD, PhD^{1,2}, C. Gregory Elliott, MD, MACP, FCCP^{4,5}

*These authors equally contributed to this work

¹ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories, Salt Lake City, UT; ²Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT.

³Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT.

⁴Department of Medicine, Intermountain Medical Center, Murray, UT; ⁵ Department of Internal Medicine University of Utah, Salt Lake City, UT

Corresponding Author: C. Gregory Elliott, MD, MACP, FCCP, Department of Medicine, Intermountain Medical Center, 5121 S. Cottonwood #307, Murray, UT 84107; email: greg.elliott@imail.org.

Key Words: Pulmonary hypertension; genetics; pulmonary veno-occlusive disease; pulmonary capillary hemangiomatosis.

Disclosures: DHB, BPS, KD-C, IN, YH, AM, MAJ, MWD, and PB-T have nothing to disclose. KLS and EP are employed by ARUP Laboratories. LMB and CGE are employed by Intermountain Healthcare. Intermountain Healthcare may receive revenue related to licensing of genetic markers and has received grants from Actelion, Bayer, Bellerophon, and Lung Biotechnology. CGE has served as a consultant for Actelion, Bayer, Ikaria and Bellerophon.

Download English Version:

<https://daneshyari.com/en/article/5600345>

Download Persian Version:

<https://daneshyari.com/article/5600345>

[Daneshyari.com](https://daneshyari.com)